Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00233935 · ClinicalTrials.gov registry record · Phase 1
Defined Green Tea Catechin Extract in Preventing Esophageal Cancer in Patients With Barrett's Esophagus
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 55
- Enrollment target
NCT00233935: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00233935 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 55 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00233935, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 55 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to test the safety of defined green tea catechin extract at different dose levels. Researchers also want to find out what effects, good and bad, it may have on individual and their risk for esophagus cancer. Esophagus cancer is an increased risk associated with Barrett's esophagus. Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. The use of defined green tea catechin extract may prevent esophageal cancer.
Interventions
- OTHER placebo
- DRUG defined green tea catechin extract
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2005-11 |
| Est. Completion | 2010-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00233935
The ClinicalTrials.gov registry entry for NCT00233935 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00233935 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00233935 about?
NCT00233935 is a clinical study titled "Defined Green Tea Catechin Extract in Preventing Esophageal Cancer in Patients With Barrett's Esophagus". The goal of this clinical research study is to test the safety of defined green tea catechin extract at different dose levels. Researchers also want to find out what effects, good and bad, it may have on individual and their risk for esophagus cancer. Esophagus cancer is an increased risk associated...
What is the current status of trial NCT00233935?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 55 participants. The study started on 2005-11. Estimated completion is 2010-11.
What interventions are being tested in trial NCT00233935?
The interventions under investigation include: placebo (OTHER), defined green tea catechin extract (DRUG).
Who is sponsoring clinical trial NCT00233935?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.